Avivagen Financial Statements From 2010 to 2025
| VIVXF Stock | USD 0.0001 0.00 0.00% |
Check Avivagen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avivagen's main balance sheet or income statement drivers, such as , as well as many indicators such as . Avivagen financial statements analysis is a perfect complement when working with Avivagen Valuation or Volatility modules.
Avivagen |
Avivagen Company Return On Asset Analysis
Avivagen's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Avivagen Return On Asset | -0.95 |
Most of Avivagen's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avivagen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Avivagen has a Return On Asset of -0.9546. This is 89.09% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Avivagen Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Avivagen's current stock value. Our valuation model uses many indicators to compare Avivagen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Avivagen competition to find correlations between indicators driving Avivagen's intrinsic value. More Info.Avivagen is rated below average in return on asset category among its peers. It is rated fourth in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Avivagen's earnings, one of the primary drivers of an investment's value.About Avivagen Financial Statements
Avivagen stakeholders use historical fundamental indicators, such as Avivagen's revenue or net income, to determine how well the company is positioned to perform in the future. Although Avivagen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Avivagen's assets and liabilities are reflected in the revenues and expenses on Avivagen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Avivagen. Please read more on our technical analysis and fundamental analysis pages.
Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada. Avivagen is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Avivagen Pink Sheet
Avivagen financial ratios help investors to determine whether Avivagen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avivagen with respect to the benefits of owning Avivagen security.